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The impact of single-nucleotide polymorphisms (SNP) of patatin-like phospholipase domain-containing protein 3
(PNPLA3) on development of hepatocellular carcinoma (HCC) is not clarified for Japanese patients with chronic
hepatitis C. The present study investigated the associations of rs738409 PNPLA3 with HCC development after the
antiviral therapy with peg-interferon and ribavirin for Japanese patients with hepatitis C virus serotype 1 and high
viral load. Of the 271 patients enrolled in the study, 20 patients developed HCC, during a median follow-up period
of 4.6 years. Multivariate analysis in the proportional hazards models revealed that sex, body mass index, platelet
counts, and alpha feroprotein (AFP) had significant associations with HCC development (p = 0.011, 0.029, 0.0002,
and 0.046, respectively). Multivariate regression analysis revealed that PNPLA3 148 M was significantly associated
with serum AFP level (p = 0.032), other than body mass index, platelet count, and alanine aminotransferase
(p = 0.0006, 0.0002, and 0.037, respectively), and that serum AFP level was significantly associated with PNPLA3
148 M (p = 0.017). Serum AFP level is an important factor in predicting HCC development after the antiviral therapy
for Japanese patients with chronic hepatitis C, the mechanism of which might involve its significant associations
with the SNP genotype of PNPLA3.
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Hepatitis C virus (HCV) infection causes chronic hepatitis,
and may progress to liver cirrhosis and hepatocellular
carcinoma (HCC). More than 170 million people worldwide
are infected with HCV, creating a serious global health
problem (Kato 2001). Combination therapy with pegylated
interferon alpha and ribavirin has a sustained virological
response (SVR) in 50% of patients with HCV genotype 1
(Firpi & Nelson 2007). Recent therapeutic regimens
using direct-acting antiviral agents have improved the
SVR up to 80% (Ghany et al. 2011a; Zeuzem et al. 2011;
Kumada et al. 2012).* Correspondence: fikeda@md.okayama-u.ac.jp
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in any medium, provided the original work is pRecently, the single-nucleotide polymorphism (SNP) of
rs738409 patatin-like phospholipase domain-containing
protein 3 (PNPLA3) has been identified for its significant
associations with liver steatosis and fibrosis in patients
with fatty liver disease and alcoholic liver disease (Romeo
et al. 2008; Valenti et al. 2010). As for patients with
chronic hepatitis C, associations of this SNP genotype
with liver steatosis, fibrosis, and the outcome of interferon
therapy have also been suggested (Trépo et al. 2011;
Valenti et al. 2011). These results were mostly obtained
from the analyses of patients of European origins; however,
analysis of Japanese patients could yield somehow different
results. A recent genome-wide association study for
Japanese patients with non-alcoholic fatty liver disease
by Kawaguchi et al. revealed that the risk variant of
PNPLA3 148 M is significantly associated with non-
alcoholic steatohepatitis, but did not show significant
differences in liver steatosis or fibrosis among the patientsan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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2012). Miyashita et al. studied the associations of the SNP
genotype of PNPLA3 with liver fibrosis and inflammation
for Japanese patients with chronic hepatitis C, without
significant associations in the results (Miyashita et al. 2012).
Takeuchi et al. reported that the SNP genotype of PNPLA3
might not affect HCC prognosis in Japanese patients with
hepatitis B virus, HCV, or non-alcoholic fatty liver diseases
(Takeuchi et al. 2013). Thus, it is possible that ethnic
differences exist in the genetic background of the patho-
genesis of chronic liver diseases.
Prediction or early detection of HCC development
after antiviral therapy is increasingly needed because of
recent improvement of antiviral therapy. The present
study investigated the associations of the SNP genotype
of PNPLA3 with HCC development after interferon
therapy in Japanese patients with chronic hepatitis C, in
order to clarify the predictive impact of the SNP genotype
of PNPLA3 on HCC development in Japanese patients
with chronic hepatitis C.
Methods
Patients
The present study enrolled 271 Japanese patients suffering
from chronic hepatitis C with HCV serotype 1 and a high
viral load 5.0 log IU/mL in real-time PCR. All patients
received 48 weeks of antiviral therapy with standard doses
of pegylated interferon alpha-2a (180 μg/week) or 2b
(1.5 μg/body weight/week) with ribavirin (600-1000 mg/
day) at either Okayama University Hospital or Kagawa
Prefectural Central Hospital. The outcomes of the
interferon therapy were evaluated, according to the
practice guidelines by the American association for the
study of liver diseases, and the Japan society of hepatology
(Ghany et al. 2011b). Hepatocellular carcinoma was ruled
out using dynamic computed tomography, magnetic
resonance imaging or ultrasonography prior to the start of
the interferon therapy. Heavy alcohol-drinking behavior
was defined as daily alcohol intake >70 grams. Patients
with hepatitis B virus co-infection, human immunodefi-
ciency virus co-infection, or autoimmune liver disease
were not included in the study. The study was performed
in accordance with the Helsinki Declaration, and the
protocols were approved by the ethics committees of the
participating institutes. All patients provided informed
consent before enrolment into the study.
Diagnosis of liver histology
Liver histology was evaluated for 219 patients prior to the
start of the interferon therapy. Liver fibrosis stage and
hepatitis activity grade were assigned for all patients by
two pathologists according to the criteria of Desmet et al.
(1994). The severity grade of hepatic steatosis was defined
according to the criteria used by Valenti et al. (2011).Genotyping of single nucleotide polymorphism
Genomic DNA was extracted from whole-blood samples
by means of a QIAamp DNA Mini Kit according to the
manufacturer’s protocol (Qiagen, Tokyo, Japan). The SNPs
of rs8099917 IL28B, and rs738409 PNPLA3 were
genotyped using the TaqMan predesigned SNP genotyping
assays, as recommended by the manufacturer (Applied
Biosystems, Tokyo, Japan). The SNP genotypes of all the
samples could be obtained with these systems.
Variations of the amino acid 70 of HCV core
For the 241 patients in the study, variations of the amino
acid 70 of HCV core (arginine or glutamine) were deter-
mined with direct sequence method. The amplifications
of HCV core in the serum were performed as previously
reported (Ikeda et al. 2010), and direct sequencing was
carried out by Big Dye termination cycle sequencing using
an ABI Prism 310 genetic analyzer (Applied Biosystems,
Foster City, CA).
Follow-up and HCC diagnosis
In accordance with the clinical practice manual from the
Japan Society of Hepatology (Makuuchi et al. 2010), HCC
diagnosis was done using ultrasonography, computed
tomography, magnetic resonance imaging, hepatic angiog-
raphy, and/or tumor biopsy, in combination with the
detection of serum levels of alpha-fetoprotein (AFP),
AFP-L3, and des gamma-carboxy prothrombin (DCP).
Only the patients without HCC at 1 year or longer after
interferon therapy were included in the study. This
follow-up period was defined as the time between the
cessation of interferon therapy and HCC diagnosis or the
latest confirmation of survival.
Statistical analysis
Data are expressed as means ± standard deviations.
Proportional hazards models were utilized to identify
the factors associated with HCC development during the
follow-up period after interferon therapy. The incidences
of HCC development were also estimated using the
Kaplan–Meier method and compared with the log-rank
test. Factors associated with the SNP genotype of PNPLA3
and AFP were analyzed by stepwise logistic regression
analysis. A value of p <0.05 was considered significant.
Statistical analysis was performed with JMP software
(SAS Institute, Cary, NC).
Results
Patient characteristics of the patients enrolled in the study
The characteristics of patients enrolled in the study are
shown in Table 1. Their average age was 57 years, and
131 patients (48%) were female. Interferon therapy
resulted in sustained virological responses in 126 patients
(46.5%), relapse in 77 patients, and null or partial
Table 1 Characteristics of the patients enrolled in the
study
Patient characteristics N = 271
Age (years) 57 ± 10†
Sex (male/female) 140/131
Body mass index 24 ± 3†
Liver fibrosis (Stage 1/2/3/4) 71/82/60/6
Hepatitis activity (Grade 1/2/3) 164/49/6
rs 8099917 of IL28B (TT/TG/GG) 198/72/1
rs 738409 of PNPLA3 (CC/CG/GG) 81/136/54
HCV core amino acids 70 (arginine/glutamine) 150/91
Alanine aminotransferase (IU/L) 66 ± 55†
Platelet count (10000 /mm3) 17 ± 6†
Alpha fetoprotein (ng/mL) 11 ± 19†
HOMA-IR 4.2 ± 8.4†
Therapeutic outcome (SVR/relapse/NVR) 126/77/68
†: Mean ± standard deviation; PNPLA3, patatin-like phospholipase domain-
containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance;
SVR, sustained virological response; NVR, null or partial virological response.
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follow-up after the interferon therapy (median period of
4.6 year), the development of HCC was observed in 20
patients (16%). The results of AFP-L3 prior to interferon
therapy were undetectable or below the lower limit of
quantification for all patients. Consistent with previous
reports (Makuuchi et al. 2010; He et al. 2009; Nishiguchi
et al. 2001), SVR contributed to lowering the risk of HCC
development (Hazards ratio 0.13, p = 0.0067, Table 2),Table 2 Proportional hazards model for the development of h
Univariate analysis
Factors Hazards ratio (range†)
Age (years) 1.0 (0.99-1.1)
Sex (1: male) 5.6 (1.6-19)
Body mass index 1.2 (1.0-1.3)
Liver fibrosis 3.8 (1.9-7.3)
Hepatitis activity 1.1 (0.44-2.6)
Liver steatosis (>30%) 2.1 (0.95-4.8)
rs 8099917 of IL28B (TT) 0.62 (0.25-1.6)
rs 738409 of PNPLA3 (148 M) 0.40 (0.17-0.97)
Amino acid 70 of HCV core (glutamine) 3.4 (0.86-14)
Alanine aminotransferase (>40 IU/L) 1.2 (0.68-2.2)
Platelet count (104/mm3) 0.77 (0.69-0.87)
Alpha fetoprotein (ng/mL) 1.1 (1.0-1.1)
HOMA-IR 0.97 (0.79-1.2)
Sustained virological response 0.13 (0.03-0.57)
Null or partial virological response 2.4 (1.0-5.9)
†: 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing pwhile patients with NVR showed a high incidence of HCC
(Hazards ratio 2.4, p = 0.048). The incidences of HCC
development were compared among patient groups formed
according to interferon therapy outcomes (Figure 1A).
The NVR patients had much higher incidence of HCC
development than the SVR or relapse patients (p = 0.0055,
the log-rank test). The SVR and relapse patients had
similar risks of HCC development during the first
2 years after interferon therapy, while relapse patients
had increased risk thereafter.
Patient characteristics associated with HCC development
after interferon therapy
We compared the patient characteristics related to HCC
development in proportional hazards models (Table 2).
Male gender, high body mass index (BMI), advanced
liver fibrosis, low platelet counts, and high levels of AFP
had significant associations with HCC development in
univariate analysis (Hazards ratio 5.6, p = 0.0062, Hazards
ratio 1.2, p = 0.0086, Hazards ratio 3.8, p <0.0001, Hazards
ratio 0.77, p <0.0001, and Hazards ratio 1.1, p = 0.0002,
respectively). The incidence of HCC development was
significantly lower in the patients with PNPLA3
148 M than in those with PNPLA3 148I (Hazards
ratio 0.4, p = 0.043). Liver steatosis and amino acid
70 of HCV core affected HCC development slightly
(Hazards ratio 2.1, p = 0.067, and Hazards ratio 3.4,
p = 0.082, respectively), while the SNP genotype of
IL28B was not associated with the risk of HCC develop-
ment (Hazards ratio 0.62, p = 0.31). Stepwise multivariate
analysis revealed that male gender, high BMI, low plateletepatocellular carcinoma
Multivariate analysis
p Hazards ratio (range†) p
0.12
0.0062 5.5 (1.5-21) 0.011








<0.0001 0.76 (0.66-0.88) 0.0002




rotein 3; HOMA-IR, homeostasis model assessment insulin resistance.
Figure 1 The incidence of HCC development after interferon therapy. The incidence of HCC development after interferon therapy was
presumed by the Kaplan–Meier method for each group by dividing the patients by the outcomes of the interferon therapy (A), serum levels of
alpha fetoproteins prior to the interferon therapy (B), and the SNP genotypes of PNPLA3 (C).
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with HCC development (Hazards ratio 5.5, p = 0.011,
Hazards ratio 1.2, p = 0.029, Hazards ratio 0.76, p = 0.0002,
and Hazards ratio 1.1, p = 0.046, respectively).
PNPLA3 148 M is independently associated with low
levels of AFP
Serum AFP levels prior to the interferon therapy
were significantly associated with HCC development
after interferon therapy (p = 0.0058, the log-rank test,
Figure 1B). Especially, patients with AFP <5 ng/mL prior
to interferon therapy showed significantly lower incidence
of HCC development than those with AFP ≥5 ng/mL
(Hazards ratio 0.09, p = 0.021). We further examined the
patient characteristics prior to the interferon therapy
regarding associations with serum AFP by stepwise logistic
regression analysis (Table 3). The results showed several
significant factors associated with serum AFP, such as BMI,
platelet count, and alanine aminotransferase (p = 0.0006,
0.0002, and 0.037, respectively). The SNP genotype of
PNPLA3 was also an independent factor associated with
serum AFP (p = 0.032). Therefore, we studied the patient
characteristics associated with the PNPLA3 148 M
genotype (Table 4). Low levels of AFP >5 ng/mL were
significantly associated with PNPLA3 148 M in stepwise
multivariate logistic regression analysis (p = 0.017). Ad-
vanced liver fibrosis was also associated with PNPLA3
148 M in univariate analysis (p = 0.028), although thisassociation did not show statistical significance in
multivariate analysis (p = 0.20).
Discussion
The impact of the SNP of PNPLA3 on interferon
therapy and HCC development after interferon ther-
apy is still undetermined for Japanese patients with
chronic hepatitis C. The present study investigated the
factors associated with HCC development after interferon
therapy for Japanese patients with chronic hepatitis C,
and is the first to clarify significant associations of the
SNP of PNPLA3 with HCC development after interferon
therapy.
The incidence of HCC development was significantly
lower in the patients with PNPLA3 148 M than in those
with PNPLA3 148I (Table 2, and Figure 1C). Considering
the roles of the SNP genotype of PNPLA3 with HCV-
related HCC, a previous report by He et al. revealed
impaired triglyceride hydrolysis in those with PNPLA3
148 M (He et al. 2009), which might work against direct
regulation of HCV in hepatic lipid metabolism, and
suppress HCC development. We explored clinical
characteristics as they related to the SNP genotype of
PNPLA3. In general, advanced liver fibrosis, high age,
and male gender have been reported as risk factors of
HCC development for patients with chronic hepatitis
C (Nishiguchi et al. 2001; Imai et al. 1998; Yoshida
et al. 1999). Liver steatosis, inflammation, insulin
Table 3 Stepwise logistic regression analysis of the factors related to alpha fetoprotein > 5 ng/mL
Univariate analysis Multivariate analysis
Factors Odds ratio (range†) p Odds ratio (range†) p
Age (years) 1.0 (1.0-1.1) 0.0024 1.0 (1.0-1.1) 0.064
Sex (1:male) 0.95 (0.58-1.6) 0.84
Body mass index 1.2 (1.1-1.3) 0.0005 1.2 (1.1-1.3) 0.0006
Liver fibrosis 2.8 (1.9-4.2) <0.0001
Hepatitis activity 1.1 (0.61-1.9) 0.83
Liver steatosis (1: >30%) 1.8 (1.1-3.0) 0.026 1.3 (0.72-2.4) 0.37
rs 8099917 of IL28B (1: TT) 1.1 (0.65-2.0) 0.67
rs738409 of PNPLA3 (1: 148 M) 0.36 (0.20-0.65) 0.0007 0.46 (0.22-0.93) 0.032
Amino acid 70 of HCV core (1: glutamine) 1.1 (0.58-2.2) 0.71
Alanine aminotransferase (1: >40 IU/L) 2.3 (1.6-3.3) <0.0001 1.6 (1.0-2.4) 0.037
Platelet count (1: >1.5x105/mm3) 0.33 (0.22-0.50) <0.0001 0.34 (0.19-0.60) 0.0002
HOMA-IR 1.0 (0.97-1.1) 0.33
†: 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance.
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HCC development. Among those factors, we could find
none significantly associated with the SNP genotype of
PNPLA3 as previously reported (Miyashita et al. 2012;
Kotronen et al. 2009).
Serum AFP was only the factor we found to be signifi-
cantly associated with the PNPLA3 genotype in the present
study; patients with PNPLA3 148 M had lower levels of
serum AFP than those with PNPLA3 148I. Meanwhile,
multiple factors such as advanced liver fibrosis, inflamma-
tion, and body composition were significantly associated
with serum AFP. Only the SNP genotype of PNPLA3 is
the significant factor that is genetically determined. The
associations of serum AFP with HCC development and
the mechanisms by which the SNP genotypes of PNPLA3
contribute to serum AFP are still unknown, and need to
be clarified in a future study.Table 4 Stepwise logistic regression analysis of the factors re
Univariate analysis
Factors Odds ratio (range†)
Age (years) 0.98 (0.95-1.0)
Sex (1: male) 0.69 (0.41-1.2)
Body mass index 1.0 (0.93-1.1)
Liver fibrosis 0.68 (0.48-0.96)
Hepatitis activity 1.3 (0.70-2.3)
Liver steatosis (1: >30%) 0.96 (0.55-1.7)
Amino acid 70 of HCV core (1: glutamine) 0.80 (0.38-1.7)
Alanine aminotransferase (1: >40 IU/L) 0.72 (0.51-1.0)
Platelet count (1: >1.5x105/mm3) 2.1 (0.93-4.7)
Alpha fetoprotein (1: >5 ng/mL) 0.36 (0.20-0.65)
HOMA-IR 0.18 (0.92-1.0)
†: 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing pRecent studies on Caucasian patients have shown that
PNPLA3 148 M was significantly associated with liver
steatosis (Poynard et al. 2003; Valenti et al. 2012; Clark
et al. 2012), while the present study on Japanese patients
showed no significant impact of the SNP genotype of
PNPLA3 on liver steatosis for the patients with chronic
hepatitis C. The high distribution of PNPLA3 148 M in
Japanese patients might be associated with ethnic differ-
ences in the role of PNPLA3 in the pathogenesis of
chronic liver disease; in the Hap Map study the prevalence
of PNPLA3 148 M was found to be 43% in the Japanese,
much higher than its prevalence in Caucasians (23%).
In conclusion, serum AFP level is an important factor in
predicting HCC development after the antiviral therapy
for Japanese patients with chronic hepatitis C, the mech-
anism of which might involve its significant associations
with the SNP genotype of PNPLA3.lated to PNPLA3 148 M
Multivariate analysis










0.0007 0.42 (0.21-0.85) 0.017
0.18
rotein 3; HOMA-IR, homeostasis model assessment insulin resistance.
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